Maria Pashayan Shares: Prognostic Implication of CYP2C19 Genotype
Maria Pashayan, Pharmacogenomics consultant at Center of Medical Genetics, posted on LinkedIn:
“In this large-scale, real-world analysis of DES-treated patients receiving clopidogrel-based dual antiplatelet therapy, high clinical risk (CHADS-P2A2RC ≥ 4 or TRS 2°P ≥ 3) was associated with worse clinical outcomes compared with low clinical risk.
Among clopidogrel-treated patients, carriage of the CYP2C19 LoF allele was linked to increased CV risk, particularly in those at high clinical risk. In low-risk patients, the prognostic relevance of the LoF allele carriage was mainly observed in those presenting with ACS.
Precision antiplatelet therapy works best when genetics + clinical risk + presentation (ACS vs CCS) are considered together—moving us closer to practical, evidence-based PGx implementation at the bedside.”
Title: Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug-Eluting Stent Implantation
Authors: Hyun Woong Park, Jae-Hwan Lee, Jin-Ok Jeong, Diana A. Gorog, Udaya S. Tantry, Byeong-Keuk Kim, Hyung Joon Joo, Kiyuk Chang, Jin-Yong Hwang, Young Bin Song, Sung Gyun Ahn, Jung-Won Suh, Woong Gil Choi, Jung Rae Cho, Jeehoon Kang, Sang Yeub Lee, Hyo-Soo Kim, Moo Hyun Kim, Do-Sun Lim, Eun-Seok Shin, Paul A. Gurbel, Young-Hoon Jeong

Discover the latest in Hemostasis Today.
-
Nov 21, 2026, 02:51Ivone Su: Raising Awareness of Venous Thromboembolism
-
Nov 21, 2026, 02:40Aniqa Gohar: One Heart Conclave – Advancing Integrated Thrombosis Care
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis